76.7 F
San Diego
Saturday, Jul 13, 2024
-Advertisement-

Orexigen Completes Initial Public Offering

Orexigen Therapeutics Inc. announced the completion of its initial public offering May 1, closing the sale of 7 million shares of common stock.

San Diego-based bio-pharmaceutical company Orexigen went public April 26 and sold its shares on the Nasdaq as OREX at $12 per share.

Lead underwriters included Merrill Lynch & Co. and J.P. Morgan Securities LLC.

Orexigen develops drugs for the treatment of central nervous system disorders with an initial focus on obesity.

Orexigen stock closed May 1 at $13.87, down 18 cents from its April 30 close.

, Andy Killion

-Advertisement-

Featured Articles

-Advertisement-
-Advertisement-

Related Articles

-Advertisement-
-Advertisement-
-Advertisement-